Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew A Spinelli

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
The Lancet. HIV|November 12, 2023
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trialRaphael J Landovitz, Brett S Hanscom, Meredith E Clement, et al.
The Journal of Clinical Investigation|December 1, 2022
Chronic viral coinfections differentially affect the likelihood of developing long COVIDMichael J Peluso, Tyler-Marie Deveau, Sadie E Munter, et al.
Medrxiv : the Preprint Server for Health Sciences|July 28, 2022
Impact of Pre-Existing Chronic Viral Infection and Reactivation on the Development of Long COVIDMichael J Peluso, Tyler-Marie Deveau, Sadie E Munter, et al.
AIDS (London, England)|July 22, 2022
Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infectionMichael J Peluso, Matthew A Spinelli, Tyler-Marie Deveau, et al.
Medrxiv : the Preprint Server for Health Sciences|March 10, 2021
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assayMichael J Peluso, Saki Takahashi, Jill Hakim, et al.
Science Advances|July 31, 2021
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assayMichael J Peluso, Saki Takahashi, Jill Hakim, et al.
Medrxiv : the Preprint Server for Health Sciences|March 24, 2021
Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19Michael J Peluso, J Daniel Kelly, Scott Lu, et al.
Open Forum Infectious Diseases|February 2, 2022
Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for MeasurementMichael J Peluso, J Daniel Kelly, Scott Lu, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
The Lancet. HIV|November 12, 2023
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trialRaphael J Landovitz, Brett S Hanscom, Meredith E Clement, et al.
The Journal of Clinical Investigation|December 1, 2022
Chronic viral coinfections differentially affect the likelihood of developing long COVIDMichael J Peluso, Tyler-Marie Deveau, Sadie E Munter, et al.
Medrxiv : the Preprint Server for Health Sciences|July 28, 2022
Impact of Pre-Existing Chronic Viral Infection and Reactivation on the Development of Long COVIDMichael J Peluso, Tyler-Marie Deveau, Sadie E Munter, et al.
AIDS (London, England)|July 22, 2022
Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infectionMichael J Peluso, Matthew A Spinelli, Tyler-Marie Deveau, et al.
Medrxiv : the Preprint Server for Health Sciences|March 10, 2021
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assayMichael J Peluso, Saki Takahashi, Jill Hakim, et al.
Science Advances|July 31, 2021
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assayMichael J Peluso, Saki Takahashi, Jill Hakim, et al.
Medrxiv : the Preprint Server for Health Sciences|March 24, 2021
Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19Michael J Peluso, J Daniel Kelly, Scott Lu, et al.
Open Forum Infectious Diseases|February 2, 2022
Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for MeasurementMichael J Peluso, J Daniel Kelly, Scott Lu, et al.
Pageof 8